Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-06-02T15:03:13.069Z Has data issue: false hasContentIssue false

Chapter 16 - Microangiopathic Hemolytic Anemia

from Section 3, Part D - Hemolytic Anemias

Published online by Cambridge University Press:  18 April 2018

By
Elaine M. Majerus  and
J. Evan Sadler
Edited by
Edward J. Benz, Jr. ,
Nancy Berliner  and
Fred J. Schiffman
Edward J. Benz, Jr.
Affiliation:
Dana Farber Cancer Institute
Nancy Berliner
Affiliation:
Brigham and Women's Hospital, Boston
Fred J. Schiffman
Affiliation:
Children's Hospital, Boston
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Anemia
Pathophysiology, Diagnosis, and Management
 , pp. 113 - 121
Publisher: Cambridge University Press
Print publication year: 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Zini, G, d’Onofrio, G, Briggs, C, Erber, W, Jou, JM, Lee, SH, et al. ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes. Int J Labor Hematol. 2012; 34(2):107–116.Google Scholar
Furlan, M, Robles, R, Galbusera, M, Remuzzi, G, Kyrle, PA, Brenner, B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998; 339(22):1578–1584.Google Scholar
Kremer Hovinga, JA, Vesely, SK, Terrell, DR, Lammle, B, George, JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010; 115(8):1500–1511.Google Scholar
Coppo, P, Bengoufa, D, Veyradier, A, Wolf, M, Bussel, A, Millot, GA, et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore). 2004; 83(4):233–244.CrossRefGoogle ScholarPubMed
Terrell, DR, Vesely, SK, Kremer Hovinga, JA, Lammle, B, George, JN. Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. Am J Hematol. 2010; 85(11):844–847.Google Scholar
Terrell, DR, Williams, LA, Vesely, SK, Lammle, B, Hovinga, JA, George, JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005; 3(7):1432–1436.Google Scholar
Miller, DP, Kaye, JA, Shea, K, Ziyadeh, N, Cali, C, Black, C, et al. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology. 2004; 15(2):208–215.Google Scholar
Miyata, T, Kokame, K, Matsumoto, M, Fujimura, Y. ADAMTS13 activity and genetic mutations in Japan. Hamostaseologie. 2013; 33(2):131–137.Google Scholar
Tarr, PI, Gordon, CA, Chandler, WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005; 365(9464):1073–1086.Google ScholarPubMed
Frank, C, Werber, D, Cramer, JP, Askar, M, Faber, M, an der Heiden, M, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med. 2011; 365(19):1771–1780.Google Scholar
Lemaire, M, Fremeaux-Bacchi, V, Schaefer, F, Choi, M, Tang, WH, Le Quintrec, M, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013; 45(5):531–536.Google Scholar
Taylor, CM, Machin, S, Wigmore, SJ, Goodship, TH, working party from the Renal Association tBCfSiH, the British Transplantation S. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol. 2010; 148(1):37–47.Google Scholar
Lotta, LA, Garagiola, I, Palla, R, Cairo, A, Peyvandi, F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat. 2010; 31(1):11–19.CrossRefGoogle ScholarPubMed
Inward, CD, Howie, AJ, Fitzpatrick, MM, Rafaat, F, Milford, DV, Taylor, CM. Renal histopathology in fatal cases of diarrhoea-associated haemolytic uraemic syndrome. British Association for Paediatric Nephrology. Pediatr Nephrol. 1997; 11(5):556–559.Google Scholar
Taylor, CM, Chua, C, Howie, AJ, Risdon, RA, British Association for Paediatric N. Clinico-pathological findings in diarrhoea-negative haemolytic uraemic syndrome. Pediatr Nephrol. 2004; 19(4):419–425.CrossRefGoogle Scholar
Scully, M, Hunt, BJ, Benjamin, S, Liesner, R, Rose, P, Peyvandi, F, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012; 158(3):323–335.Google Scholar
Loirat, C, Fremeaux-Bacchi, V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011; 6:60.Google Scholar
Noris, M, Caprioli, J, Bresin, E, Mossali, C, Pianetti, G, Gamba, S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010; 5(10):1844–1859.Google Scholar
Rieger, M, Mannucci, PM, Kremer Hovinga, JA, Herzog, A, Gerstenbauer, G, Konetschny, C, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005; 106(4):1262–1267.Google Scholar
Schwartz, J, Winters, JL, Padmanabhan, A, Balogun, RA, Delaney, M, Linenberger, ML, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013; 28(3):145–284.Google Scholar
O’Brien, KL, Price, TH, Howell, C, Delaney, M. The use of 50% albumin/plasma replacement fluid in therapeutic plasma exchange for thrombotic thrombocytopenic purpura. J Clin Apher. 2013; 28(6):416–421.CrossRefGoogle ScholarPubMed
Zhan, H, Streiff, MB, King, KE, Segal, JB. Thrombotic thrombocytopenic purpura at the Johns Hopkins Hospital from 1992 to 2008: clinical outcomes and risk factors for relapse. Transfusion. 2010; 50(4):868–874.Google Scholar
Westwood, JP, Webster, H, McGuckin, S, McDonald, V, Machin, SJ, Scully, M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost. 2013; 11(3):481–490.Google Scholar
Hie, M, Gay, J, Galicier, L, Provot, F, Presne, C, Poullin, P, et al. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura: experience of the French Thrombotic Microangiopathies Reference Center. Blood. 2014; 124(2):204–210.Google Scholar
Bharat, A, Xie, F, Baddley, JW, Beukelman, T, Chen, L, Calabrese, L, et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthr Care Res. 2012; 64(4):612–615.Google Scholar
Lunel-Fabiani, F, Masson, C, Ducancelle, A. Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation. Joint, bone, spine: revue du rhumatisme. Joint Bone Spine. 2014; 81(6):478–484.Google Scholar
Shortt, J, Oh, DH, Opat, SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med. 2013; 368(1):90–92.Google Scholar
Ahmad, HN, Thomas-Dewing, RR, Hunt, BJ. Mycophenolate mofetil in a case of relapsed, refractory thrombotic thrombocytopenic purpura. Eur J Haematol. 2007; 78(5):449–452.Google Scholar
Li, GW, Rambally, S, Kamboj, J, Reilly, S, Moake, JL, Udden, MM, et al. Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report. Transfusion. 2014; 54(5):1221–1224.Google Scholar
Cataland, SR, Peyvandi, F, Mannucci, PM, Lammle, B, Kremer Hovinga, JA, Machin, SJ, et al. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol. 2012; 87(4):430–432.Google Scholar
Callewaert, F, Roodt, J, Ulrichts, H, Stohr, T, van Rensburg, WJ, Lamprecht, S, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood. 2012; 120(17):3603–3610.Google Scholar
Scully, M, Thomas, M, Underwood, M, Watson, H, Langley, K, Camilleri, RS, et al. Congenital and acquired thrombotic thrombocytopenic purpura and pregnancy: presentation, management and outcome of subsequent pregnancies. Blood. 2014; 124(2):211–219.Google Scholar
Menne, J, Nitschke, M, Stingele, R, Abu-Tair, M, Beneke, J, Bramstedt, J, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ. 2012; 345:e4565.Google Scholar
Braune, SA, Wichmann, D, von Heinz, MC, Nierhaus, A, Becker, H, Meyer, TN, et al. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome. Crit Care Med. 2013; 41(7):1702–1710.Google Scholar
Wong, CS, Mooney, JC, Brandt, JR, Staples, AO, Jelacic, S, Boster, DR, et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis. 2012; 55(1):33–41.Google Scholar
Legendre, CM, Licht, C, Muus, P, Greenbaum, LA, Babu, S, Bedrosian, C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368(23):2169–2181.Google Scholar
Fremeaux-Bacchi, V, Fakhouri, F, Garnier, A, Bienaime, F, Dragon-Durey, MA, Ngo, S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013; 8(4):554–562.Google Scholar
Noris, M, Remuzzi, G. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens. 2013; 22(6):704–712.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×